Protective effects of yangambin on cardiovascular hyporeactivity to catecholamines in rats with endotoxin-induced shock

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 363, Issue 3, 2001, Pages 267-275

  Araujo C V ^a   Barbosa Filho, José M ^b   Cordeiro, R S B ^a   Tibirica E ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF PARAÍBA   (Brazil)

Author keywords

Cardiovascular collapse; Endotoxaemia; Endotoxic shock; PAF receptor antagonist; Yangambin

Indexed keywords

APAFANT; BACTERIUM LIPOPOLYSACCHARIDE; CATECHOLAMINE; ENDOTOXIN; GALACTOSAMINE; NORADRENALIN; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; YANGAMBIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG STRUCTURE; ESCHERICHIA COLI; HEART FAILURE; HEART OUTPUT; HEART PROTECTION; HYPOTENSION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PATHOGENESIS; RAT; SEPTIC SHOCK; SURVIVAL; TREATMENT OUTCOME; VASCULAR RESISTANCE;

ANIMALS; AZEPINES; BLOOD PRESSURE; CARDIAC OUTPUT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FURANS; HEART RATE; LIGNANS; LIPOPOLYSACCHARIDES; MALE; NOREPINEPHRINE; PLATELET AGGREGATION INHIBITORS; PLATELET MEMBRANE GLYCOPROTEINS; RATS; RATS, WISTAR; RECEPTORS, CELL SURFACE; RECEPTORS, G-PROTEIN-COUPLED; SHOCK, CARDIOGENIC; SHOCK, SEPTIC; TRIAZOLES; VASOCONSTRICTOR AGENTS;

EID: 0035115057     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002100000350     Document Type: Article

References (48)

1. Platelet activating factor and its role in trauma, shock, and sepsis
2. Neurohormonal host defence in endotoxin shock
3. Acute circulatory collapse caused by platelet-activating factor (PAF-acether) in dogs
4. Let's agree on terminology: Definitions of sepsis
5. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies sepsis
6. Platelet activating factor impairs pressor responses to noradrenaline in the anaesthetized rat but does not mediate endotoxin-induced hyporeactivity
7. Perspectives in platelet-activating factor research
8. Effect of platelet-activating factor on guinea-pig papillary muscle
9. Protective effect of WEB 2086, a novel antagonist of platelet-activating factor, in endotoxin shock
10. Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor
11. Pharmacological profile of epiyangambin: A furofuran lignan with PAF antagonist activity
12. Yangambin, a new naturally-occurring platelet-activating factor receptor antagonist: In vitro pharmacological studies
13. Yangambin, a new naturally-occurring platelet-activating factor receptor antagonist: In vivo pharmacological studies
14. Lignans and other non-alkaloidal constituents from Rollinea mucosa
15. Platelet activating factor (PAF) involvement in endotoxin-induced hypotension in rats. Studies with PAF-receptor antagonist kadsurenone
16. Role of platelet-activating factor and prostanoids in hemodynamic changes in rat experimental endotoxic shock
17. Requirement for lipopolysaccharide-responsive macrophages in galactosamine-induced sensitization to endotoxin
18. Galactosamine-induced sensitization to the lethal effects of endotoxin
19. Effects of UR-12633, a new antagonist of platelet-activating factor, in rodent models of endotoxic shock
20. Protective effect of SR27417, a novel PAF-antagonist, on lethal anaphylactic and endotoxic-induced shocks in mice
21. Platelet-activating factor type activity in plasma from patients with septicemia and other diseases
22. Septic endotoxemia
23. Lipopolysaccharide-induced hypotension and vascular hyporeactivity in the rat: Tissue analysis of nitric oxide synthase mRNA and protein expression in the presence and absence of dexamethasone, NG-monomethyl-L-arginine or indomethacin
24. Effects of antisense oligonucleotide to iNOS on hemodynamic and vascular changes induced by LPS
25. Synthesis of PAF-acether and blood volume changes in gram-negative sepsis
26. Effects of TCV-309, a novel PAF antagonist, on circulatory shock and hematological abnormality induced by endotoxin in dogs
27. Attenuation of endotoxin-induced pathophysiology by a new potent PAF receptor antagonist
28. Pathophysiological mechanisms of sudden death induced by platelet-activating factor
29. Lethal toxicity of lipopolysaccharide and tumor necrosis factor in normal and D-galactosamine-treated mice
30. Acetyl glyceryl ether phosphorylcholine (AGEPC), a putative mediator of cardiac anaphylaxis in the guinea pig
31. Lignans from Rollinia species
32. Platelet-activating factor antagonists in experimental shock
33. Effect of TCV-309, a novel platelet activating factor antagonist, on hemodynamics in dogs with endotoxin-induced shock
34. Lignans with platelet-activating factor antagonist activity from Magnolia biondii
35. Effect of dexamethasone on the onset and persistence of vascular hyporeactivity induced by E. coli lipopolysaccharide in rats
36. 4
37. Platelet activating factor (PAF) and tumor necrosis factor-alpha (TNF alpha) interactions in endotoxemic shock: Studies with BN 50739, a novel PAF antagonist
38. Protective effects of yangambin, a natural platelet-activating factor (PAF) receptor antagonist, on the anaphylactic shock in rats
39. Pharmacological modulation of PAF: A therapeutic approach to endotoxin shock
40. Nitric oxide-mediated hyporeactivity to noradrenaline precedes the induction of nitric oxide synthase in endotoxin shock
41. Platelet-activating factor contributes to the induction of nitric oxide synthase by bacterial lipopolysaccharide
42. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in mice
43. Inhibition of nitric oxide synthesis reduces the hypotension induced by bacterial lipopolysaccharides in the rat in vivo
44. Antagonistic effect of yangambin on platelet-activating factor (PAF)-induced cardiovascular collapse
45. PAF-acether today-relevance for acute experimental anaphylaxis
46. Myocardial depression characterizes the fatal course of septic shock
47. Tetramethyl-pyradizine prevents inducible NO synthase expression and improves survival in rodent models of endotoxic shock
48. Platelet-activating factor receptor antagonist attenuates endotoxin-induced vascular hyporeactivity in the pithed rat